KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to -$1.3 billion.

  • Jazz Pharmaceuticals' Enterprise Value rose 4021.69% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 4021.69%. This contributed to the annual value of -$2.4 billion for FY2024, which is 6018.38% down from last year.
  • Jazz Pharmaceuticals' Enterprise Value amounted to -$1.3 billion in Q3 2025, which was up 4021.69% from -$1.2 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Enterprise Value registered a high of -$490.8 million during Q1 2022, and its lowest value of -$2.4 billion during Q4 2024.
  • Its 5-year average for Enterprise Value is -$1.3 billion, with a median of -$1.3 billion in 2023.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 19896.34% in 2021, then surged by 7659.94% in 2022.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Enterprise Value stood at -$591.4 million in 2021, then tumbled by 49.04% to -$881.5 million in 2022, then tumbled by 70.88% to -$1.5 billion in 2023, then plummeted by 60.18% to -$2.4 billion in 2024, then soared by 45.04% to -$1.3 billion in 2025.
  • Its Enterprise Value was -$1.3 billion in Q3 2025, compared to -$1.2 billion in Q2 2025 and -$1.9 billion in Q1 2025.